Paul Haluska
Mayo Clinic · 290 works · 7,440 citations · h-index 47
Top works
- Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
- Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
- Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors
- Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer
- The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
- In vitro and In vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417
- Cancer and Pregnancy: Parallels in Growth, Invasion, and Immune Modulation and Implications for Cancer Therapeutic Agents
- Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
- The Insulin-Like Growth Factor System in Cancer
- Farnesyl transferase inhibitors as anticancer agents
- Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
- Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
- IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons
- Epithelial ovarian cancer experimental models
- Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape
- Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer
- Hormone response in ovarian cancer: time to reconsider as a clinical target?
- Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development
- Interaction between human topoisomerase I and a novel RING finger/arginine-serine protein